Advances in Lung & GI Community Oncology 2025 скачать в хорошем качестве

Advances in Lung & GI Community Oncology 2025

This program is supported by an educational grant from Pfizer. It is designed only for healthcare professionals in the United States. As precision oncology advances, integrating molecular testing and targeted therapies into first-line management for BRAF V600E–mutant metastatic colorectal cancer (mCRC) and metastatic non-small cell lung cancer (mNSCLC) remains a clinical and educational priority. In this interactive 45-minute live webinar, Dr. Zev Wainberg will explore practical, evidence-based strategies to optimize first-line treatment selection, improve toxicity management, and strengthen confidence in biomarker-driven decisions. Using real-world cases, Dr. Wainberg will translate emerging data and guideline updates into actionable insights for both community and academic oncology teams. Session Highlights Addressing Key Gaps in Practice: Personalize first-line therapy: Explore evidence-based strategies and real-world cases to confidently select and sequence BRAF-targeted regimens for patients with BRAF V600E–mutant mCRC and mNSCLC. Manage toxicities proactively: Gain practical tools to anticipate, monitor, and manage adverse events to sustain treatment continuity and improve patient outcomes. Integrate biomarkers into decision-making: Strengthen confidence in selecting and interpreting biomarker tests (BRAF, RAS, MSI/MMR) to guide precision treatment planning across tumor types. Who should attend This activity is designed for healthcare professionals in community and academic settings involved in the selection, prescription, and management of first-line targeted therapies for patients with BRAF V600E–mutant mCRC or mNSCLC, including: Medical oncologists Oncology nurses Nurse practitioners Physician assistants Pharmacists Speaker Bio Zev A. Wainberg, MD, is Professor of Medicine at the David Geffen School of Medicine at UCLA, where he serves as Co-Director of the UCLA Gastrointestinal (GI) Oncology Program and Director of the Early Phase Clinical Research Program at the UCLA Jonsson Comprehensive Cancer Center. An internationally recognized expert in gastrointestinal and thoracic cancers, Dr. Wainberg has led and authored numerous clinical trials investigating novel targeted and immunotherapeutic strategies. His research and leadership continue to shape best practices in biomarker-driven care for patients with advanced malignancies. Learning objectives Apply clinical evidence, guidelines, and patient-specific factors to select and personalize first-line BRAF-targeted therapy for patients with BRAF V600E-mutant mCRC and mNSCLC Implement proactive strategies to monitor and manage adverse events associated with BRAF-targeted regimens to maintain treatment continuity and optimize patient outcomes Demonstrate the ability to identify, order, and interpret appropriate biomarker tests (e.g., BRAF, RAS, MSI/MMR) to inform first-line treatment decisions in mCRC and mNSCLC Continuing Education Information Please read the full disclosures and accreditation information here before joining this event: https://app.medalleducation.com/event...